About ALAR
ALAR is a company based in Taichung (Taiwan) founded in 2016. The company has 27 employees. ALAR operates in a competitive market with competitors including Indivior, Biotie, IgGenix, Ethypharm and Braeburn, among others.
- Headquarter Taichung, Taiwan
- Employees 27
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website alarpharm.com
- Legal Name Alar Pharmaceuticals Inc
- Annual Revenue$2.75 M-52.67as on Dec 31, 2025
- Net Profit-$79.68 M-538.54as on Dec 31, 2025
- EBITDA-$162.93 M-154.33as on Dec 31, 2025
- Employee Count27
People of ALAR
1 people are tracked at ALAR (1 in leadership); the tracked headcount is 27.
| Name | Role | Group |
|---|---|---|
Yung Shun Wen | CEO | Leadership |
Complete people profiles for ALAR
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ALAR
ALAR is a publicly listed company on the TPEX with ticker symbol 6785 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Jan 2024
- Listed onTT: 6785
- Listed entityAlar Pharmaceuticals Inc
- Exchange sectorHealth technology
- ISINTW0006785009
- Share price88.10 TWD (-2.97% on the day) · 2026-10-08
- Market capitalisation5,885,080,167.00 TWD
- EPS (diluted, trailing year)-1.08 TWD
- Dividend yield0.11%
- Volume (last session)83,057
Financials of ALAR
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.8M TWD | -79.7M TWD | -162.9M TWD |
| 2024 | 5.8M TWD | 18.2M TWD | -64.1M TWD |
| 2023 | 469.3M TWD | 382.6M TWD | 388.9M TWD |
| 2022 | 800,000 TWD | -19.9M TWD | -43.3M TWD |
| 2021 | – | -64.2M TWD | -89.9M TWD |
Detailed financial statements for ALAR
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of ALAR
ALAR operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Biotie, IgGenix, Ethypharm and Braeburn, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indivior.com | 2014 | Richmond Hill, United States | – | 1,051 | Therapeutics for opioid addiction treatment are developed and commercialized. | |
| biotie.com | 1998 | Turku, Finland | $149.81M | 27 | Drugs for neurodegenerative and psychiatric disorders are developed by Biotie. | |
| iggenix.com | 2019 | San Francisco, United States | $75M | – | Therapeutic solutions for food allergies are developed via antibody platforms. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | – | Therapies for pain and addiction treatment are developed. | |
| braeburnrx.com | 2012 | Philadelphia, United States | $110M | – | Long-acting therapies for opioid addiction and chronic pain are developed. | |
| opiant.com | 2005 | Santa Monica, United States | – | 31 | Therapeutics for addictive and eating disorders are developed. | |
| amygns.com | 2015 | San Francisco, United States | $7.05M | – | Therapies for substance use disorders are developed by Amygdala Neurosciences. | |
| 4p-pharma.com | 2014 | Lille, France | $18.49M | – | French Biotech startup that develops to clinical trial stage the molecules it has in-licensed | |
| cessationtherapeutics.com | 2017 | San Jose, United States | $6.76M | – | Developer of immunotherapy based vaccines to manage addictions | |
| titanpharm.com | 1992 | San Francisco, United States | – | 11 | A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases |
Detailed competitors of ALAR
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alar
Complete news archive for ALAR
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ALAR
10 companies that operate in the same segment as ALAR (Toxicology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutic solutions for food allergies are developed via antibody platforms. | 2019 | San Francisco, California, United States | USD 75 M | – | – | |
Therapeutics for substance use disorders, including opioid-related conditions, are developed. | 2020 | Oakland, California, United States | USD 70 M | – | – | |
Drug delivery solutions via single-walled carbon nanotubes are offered. | 2008 | Houston, Texas, United States | USD 2.5 M | USD 5.07 M | 9 | |
Non-invasive drug testing technology is developed using fingerprints. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 25.71 M | – | – | |
Provides toxicology, chemistry, and consultancy services for agrochemical industries. | 2020 | Vapi, Gujarat, India | – | – | – | |
Instruments for rapid human DNA identification are developed. | 2006 | Pleasanton, California, United States | USD 92.06 M | USD 22.5 B | 78 | |
Oral therapies for snake bite treatment are developed. | 2015 | Corte Madera, California, United States | USD 16.48 M | – | – | |
Quantitative urine drug testing is provided for patient monitoring. | 2011 | San Diego, California, United States | – | – | 358 | |
Point-of-care platforms for heavy metal toxicity diagnostics are developed. | 1968 | Billerica, Massachusetts, United States | USD 34 M | – | – | |
Real-time trace gas analysis solutions are delivered using SIFT-MS technology. | 2002 | Christchurch, New Zealand | USD 11.9 M | USD 23.52 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ALAR
ALAR was founded in 2016.
ALAR is headquartered in Taichung, Taiwan.
Yung Shun Wen is the current CEO of ALAR.
ALAR has 27 employees.
Founded in 2016 and based in Taichung, Taiwan, the company operates in the pharmaceutical sector, focusing on drug development for opioid use disorder and depressive disorder. Products such as ALA-1000 and ALA-1300 target opioid addiction, while ALA-2000 addresses opioid and alcohol addiction, and ALA-3000 treats treatment-resistant depression. A long-acting release platform is utilized to create low-viscosity formulations with small injection volumes and consistent drug release.
Yes, ALAR is publicly traded on TPEX under the ticker symbol 6785.